Increased tissue factor expression on circulating monocytes in chronic HIV infection: Relationship to in vivo coagulation and immune activation

Blood

Volumn 115, Issue 2, 2010, Pages 161-167

  Funderburg, Nicholas T ^a   Mayne, Elizabeth ^b   Sieg, Scott F ^a   Asaad, Robert ^a   Jiang, Wei ^a   Kalinowska, Magdalena ^a   Luciano, Angel A ^a,c   Stevens, Wendy ^b   Rodriguez, Benigno ^a   Brenchley, Jason M ^d   Douek, Daniel C ^d   Lederman, Michael M ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; FLAGELLIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PLASMIN; THROMBOPLASTIN; BIOLOGICAL MARKER; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; IL6 PROTEIN, HUMAN;

ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL SURFACE; CHRONIC DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FIBRINOLYSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IN VIVO STUDY; LIFESPAN; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOGENESIS; VIRUS REPLICATION; ADULT; BIOSYNTHESIS; BLOOD; CELL CULTURE; GENE EXPRESSION REGULATION; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; METABOLISM; RISK FACTOR; THROMBOSIS;

ADULT; ANTIGENS, CD14; BIOLOGICAL MARKERS; CELLS, CULTURED; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FLAGELLIN; GENE EXPRESSION REGULATION; HIV; HIV INFECTIONS; HUMANS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; MONOCYTES; RISK FACTORS; THROMBOPLASTIN; THROMBOSIS; VIRUS REPLICATION;

EID: 75649127335     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-03-210179     Document Type: Article

References (36)

1. Tabib A, Leroux C, Mornex JF, Loire R. Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus- positive patients. Coron Artery Dis. 2000;11(1): 41-46.
2. Matta F, Yaekoub AY, Stein PD. Human immunodeficiency virus infection and risk of venous thromboembolism. Am J Med Sci. 2008;336(5): 402-406.
3. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intimamedia thickness in patients with HIV infection. Circulation. 2004;109(13):1603-1608.
4. Hsue PY, Hunt PW, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS. 2006;20(18): 2275-2283.
5. Hsue PY, Giri K, Erickson S, et al. Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation. 2004;109(3):316-319.
6. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17(8):1179-1193.
7. d'Arminio A, Sabin CA, Phillips AN, et al. Cardio-and cerebrovascular events in HIV-infected persons. AIDS. 2004;18(13):1811-1817.
8. Kaplan RC, Kingsley LA, Gange SJ, et al. Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS. 2008;22(13):1615-1624.
9. Mangili A, Gerrior J, Tang AM, et al. Risk of cardiovascular disease in a cohort of HIV-infected adults: a study using carotid intima-media thickness and coronary artery calcium score. Clin Infect Dis. 2006;43(11):1482-1489.
10. Mooser V. Atherosclerosis and HIV in the highly active antiretroviral therapy era: towards an epidemic of cardiovascular disease? AIDS. 2003; 17[suppl 1]:S65-S69.
11. Periard D, Cavassini M, Taffe P, et al. High prevalence of peripheral arterial disease in HIV-infected persons. Clin Infect Dis. 2008;46(5):761-767.
12. Stein JH. Cardiovascular risks of antiretroviral therapy. N Engl J Med. 2007;356(17):1773-1775.
13. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5(10): e203.
14. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12(12):1365-1371.
15. Marchetti G, Bellistri GM, Borghi E, et al. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS. 2008;22(15):2035-2038.
16. Jiang W, Lederman MM, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis. 2009;199(8):1177-1185.
17. Funderburg N, Luciano AA, Jiang W, Rodriguez B, Sieg SF, Lederman MM. Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis. PLoS One. 2008; 3(4):e1915.
18. Meier A, Alter G, Frahm N, et al. MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded toll-like receptor ligands. J Virol. 2007;81(15):8180-8191.
19. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues: implications for disorders of hemostasis and thrombosis. Am J Pathol. 1989;134(5):1087-1097.
20. Niemetz J. Tissue-factor-endowed leukocytes do cause thrombosis. Blood. 2005;106(4):1506; author reply 1507.
21. Kitchens RL, Thompson PA. Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res. 2005;11(4):225-229.
22. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999;179(4):859-870.
23. Deeks SG, Kitchen CM, Liu L, et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood. 2004;104(4):942-947.
24. Semeraro N, Biondi A, Lorenzet R, Locati D, Mantovani A, Donati MB. Direct induction of tissue factor synthesis by endotoxin in human macrophages from diverse anatomical sites. Immunology. 1983;50(4):529-535.
25. Oeth PA, Parry GC, Kunsch C, Nantermet P, Rosen CA, Mackman N. Lipopolysaccharide induction of tissue factor gene expression in monocytic cells is mediated by binding of c-Rel/p65 heterodimers to a kappa B-like site. Mol Cell Biol. 1994;14(6):3772-3781.
26. Martin DM, Boys CW, Ruf W. Tissue factor: molecular recognition and cofactor function. FASEB J. 1995;9(10):852-859.
27. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359(9):938-949.
28. Mackman N. Role of tissue factor in hemostasis and thrombosis. Blood Cells Mol Dis. 2006;36(2): 104-107.
29. Yan ZQ, Hansson GK. Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev. 2007;219:187-203.
30. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol. 2008;8(10):802-815.
31. Taylor FB Jr, Chang A, Ruf W, et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock. 1991; 33(3):127-134.
32. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FB Jr, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest. 1993;91(6):2850-2860.
33. Leatham EW, Bath PM, Tooze JA, Camm AJ. Increased monocyte tissue factor expression in coronary disease. Br Heart J. 1995;73(1):10-13.
34. Jude B, Zawadzki C, Susen S, Corseaux D. Relevance of tissue factor in cardiovascular disease. Arch Mal Coeur Vaiss. 2005;98(6):667-671.
35. Al-Saady NM, Leatham EW, Gupta S, Kwan JT, Eastwood JB, Seymour CA. Monocyte expression of tissue factor and adhesion molecules: the link with accelerated coronary artery disease in patients with chronic renal failure. Heart. 1999; 81(2):134-140.
36. Annex BH, Denning SM, Channon KM, et al. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation. 1995;91(3):619-622.